Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma
OBJECTIVES: I. Assess the therapeutic role of tamoxifen in patients with inoperable
hepatocellular carcinoma in terms of overall survival and quality of life.
OUTLINE: This is a randomized, double blind, placebo controlled study of tamoxifen. Patients
are randomized to one of 3 treatment arms. Arm I: Patients receive placebo orally twice
daily for one year. Arms II and III: Patients receive tamoxifen, at 1 of 2 different doses,
orally twice daily for one year. Quality of life is assessed before treatment and then
monthly thereafter. Patients are followed monthly until death.
PROJECTED ACCRUAL: This study will accrue 300 patients.
Interventional
Allocation: Randomized, Primary Purpose: Treatment
Pierce Chow, MD, PhD, MBBS, FRCS, FAMS
Study Chair
National Cancer Centre, Singapore
United States: Federal Government
NMRC-AHCC01
NCT00003424
April 1997
August 2009
Name | Location |
---|